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Abstract
Objective:  Uric  acid  (UA)  is  the  end  product  of  adenosine  triphosphate  degradation,  and  could
increase due  to  hypoxia.  We  investigated  the  association  of  UA  metabolites  with  nocturnal
hypoxemia,  apnea-hypopnea  index  (AHI),  noninvasive  mechanical  ventilation  (NIMV)  usage  and
ﬁve-year mortality.
Materials/subjects  and  methods:  We  obtained  urinary  specimen  before  and  after  the  night
polysomnography  in  order  to  measure  UA  excretion  and  overnight  change  in  urinary
UA/creatinine  ratio  (UA/Cr)  in  75  subjects  (14  controls,  15  chronic  obstructive  pulmonary
disease (COPD)  without  nocturnal  hypoxemia  (NH),  15  COPD  with  NH,  16  obstructive  sleep
apnea syndrome  (OSAS)  without  NH,  15  OSAS  with  NH).  Percentage  of  time  spent  below  SaO2
of  90%  (T90%)  for  >10%  of  sleep  time  was  considered  as  nocturnal  hypoxemia.  Patients  were
contacted  after  5  years  with  a  questionnaire  including  information  on  the  use  of  NIMV  treatment
(n: 58)  and  urinary  specimen  analysis  (n:  35).
Results:  T90%  was  found  to  be  signiﬁcantly  correlated  with  UA  excretion  (coefﬁcient:  0.005,
95%CI: 0.003--0.007)  and  UA/Cr  (coefﬁcient:  0.8,  95%CI:  0.3--1.2)  after  adjustments  for  age,
gender, body  mass  index  and  apnea-hypopnea  index.  Median  and  IQR  (interquartile  range)  of
baseline UA  excretion  were  0.79  (0.51--0.89)  and  0.41  (0.31--0.55)  in  10  deceased  and  58  sur-
viving patients,  respectively  (p  =  0.001).  UA  excretion  median  and  IQR  of  baseline  and  5  years
of NIMV  treatment  were  0.41  (0.36--0.57)  and  0.29  (0.23--0.37),  respectively  (p  =  0.01).
Conclusion:  UA  excretion,  as  a  marker  of  tissue  hypoxia,  may  be  useful  in  the  management  of
OSA and  COPD  patients.sa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.U.  All  rights©  2015  Sociedade  Portugue
reserved.∗ Corresponding author.
E-mail address: yeldavatansever@hotmail.com (Y. Varol).
ttp://dx.doi.org/10.1016/j.rppnen.2015.06.002
173-5115/© 2015 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. All rights reserved.
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less  than  80%  of  the  predicted  value  after  bronchodilator  useUric  acid  excretion  in  obstructive  sleep  apnea  and  COPD  
Introduction
Obstructive  sleep  apnea  is  characterized  by  recurrent
episodes  of  partial  (hypoapnea)  or  complete  (apnea),
obstruction  of  the  upper  airway  during  sleep,  and  is  asso-
ciated  with  episodes  of  arousal  and/or  oxyhemoglobin
desaturation.1 Uric  acid  (UA),  which  is  the  end  product  of
adenosine  triphosphate  (ATP)  degradation,  increases  in  body
ﬂuids  in  the  case  of  increased  anaerobic  metabolism  induced
by  cellular  hypoxia.2--5 Increased  levels  of  ATP  degradation
products  in  body  ﬂuids  were  reported  in  clinical  condi-
tions  with  tissue  hypoxia,  such  as  infant  respiratory  distress
syndrome,6,7 exercise8--12 and  acute  respiratory  failure.13,14
Hasday  and  Grum  reported  that  the  overnight  change  in
urinary  UA/creatinine  ratio  (UA/Cr)  could  reﬂect  tissue
hypoxia  in  obstructive  sleep  apnea  syndrome  (OSAS).15
Hypoxemia  occurs  during  sleep  in  the  case  of  OSAS,  and
during  both  sleep  and  daytime  in  the  case  of  chronic  obstruc-
tive  pulmonary  disease  (COPD).  Since  sleep-associated
hypoxemia  has  been  implicated  in  the  pathophysiology  of
several  abnormalities  of  COPD  and  OSA  syndrome,  urinary
UA,  as  a  marker  of  tissue  hypoxia,  may  be  useful  in  deﬁning
the  higher  risk  groups  in  relation  to  these  two  diseases.16,17
In  this  study,  the  correlation  of  urinary  UA  and  UA/Cr
with  nocturnal  hypoxemia  and  apnea-hypopnea  index  (AHI)
was  investigated  in  a  follow-up  study  including  patients  with
COPD  and  patients  with  OSA  syndrome.  Additionally,  these
patients  were  contacted  5  years  later  and  the  correlation
between  ﬁrst  night  UA  measurements  and  mortality  and  the
correlation  between  the  change  in  UA  levels  during  ﬁve  years
and  use  of  noninvasive  ventilation  (NIV)  treatment  were
investigated.
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aterial and methods
atient  selection
he  study  enrolled  75  patients,  including  31  cases  with  OSA
yndrome,  30  with  COPD,  and  a control  group  including
4  subjects  who  were  eligible  and  gave  informed  con-
ent  to  participate  in  this  prospective  follow-up  study.  The
iagnostic  criteria  for  OSA  and  CPAP  (continuous  positive
irway  pressure)  treatment  were  determined  according  to
he  standard  criteria  published  by  the  American  Academy
f  Sleep  Medicine  (AASM).18 The  criteria  are  deﬁned  below.
SA  patients  displayed  at  least  two  of  the  following  three
ymptoms:  snoring,  witnessed  apnea,  and  excessive  day-
ime  sleepiness.  Their  AHI  score  was  5  or  higher  in  the
vernight  polysomnography  (PSG).18 CPAP  treatment  was
iven  if  AHI  >  30  or  AHI  between  5  and  30  with  a  cardiovascu-
ar  co-morbidity.  OSAS  patients  did  not  have  COPD  deﬁned
y  spirometry.
Patients  were  routinely  called  after  3  months  and  1  year
eriods  to  our  outpatients  clinic.  For  reassessment  after
 years  patients  were  contacted  by  telephone  interview
n  =  68,  58  alive,  10  died).  35  of  them  agreed  to  give  uric
cid  samples  (blood  and  urine)  (Fig.  1).  The  compliance  of
PAP  use  was  evaluated  after  follow-up.
The  recruitment  criteria  for  COPD  included  a  history  of  10
r  more  pack-years  of  smoking  or  a  history  of  biomass  expo-
ure,  a  forced  expiratory  volume  in  one  second  (FEV  1)  ofPSG, 
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phy,  PFT:  pulmonary  function  tests,  UA:  uric  acid,  NIMV:  non
syndrome  nocturnal  normoxemic,  OSAS-NH:  obstructive  sleep
e  pulmonary  disease  nocturnal  normoxemic,  COPD-NH:  chronic
nd  a  ratio  of  FEV  1  to  forced  vital  capacity  (FVC)  of  0.7  or
ess  after  bronchodilator  use.19 The  condition  of  the  patients
as  graded  according  to  the  stages  of  disease  deﬁned  by
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he  Global  initiative  for  chronic  Obstructive  Lung  Disease
GOLD).20 COPD  patients  had  moderate  to  severe  COPD  dis-
ase  without  daytime  hypoxia.21 Patients  who  displayed  any
f  the  symptoms  of  snoring  and/or  witnessed  apnea  were
ot  enrolled  in  the  study.  The  AHI  scores  were  below  5  in  the
vernight  PSG.  The  subjects  in  the  control  group  had  neither
SA  nor  COPD.  They  were  admitted  to  the  sleep  laboratory
ith  a  complaint  of  snoring.  Patients  with  OSA  and  COPD,
ho  spent  >10%  of  sleep  time  with  oxyhemoglobin  saturation
SaO2)  below  90%  were  classiﬁed  as  nocturnal  hypoxemic
NH).  Personal  characteristics  and  disease-related  factors
ere  assessed  based  on  patient  records.  Flowchart  of  the
ubjects  and  procedures  are  presented  in  Fig.  1.
Patients  were  not  enrolled  in  the  study  if  they  had  any
isease  or  medication  that  might  alter  the  metabolism  or
rinary  excretion  of  uric  acid,  as  in  the  following:
.  Excessive  UA  production:  Physician-diagnosed
gout,  diabetes  mellitus,  hemolytic  anemia,  myelo-
lymphoproliferative  disease,  psoriasis,  Paget’s  disease,
or  glucose-6-phosphatase  deﬁciency  or  glycogen  storage
disease.
.  Decreased  UA  excretion:  Physician-diagnosed  renal  fail-
ure,  acidosis,  sarcoidosis,  lead  intoxication  or  berylliosis.
.  Medication:  Salicylic  acid  (in  excess  of  2  g/day),  diuretic,
cyclosporine,  levodopa,  phenylbutazone  (in  excess  of
200  mg/day),  ethambutol,  pyrazinamide,  nicotinic  acid,
nitroglycerin  (intravenous)  theophylline,  allopurinol.
.  Alcohol  intake  on  the  day  of  PSG  and  follow-up.
.  Exercise  on  the  day  of  PSG.
Subjects  were  asked  not  to  exercise  or  consume  alcohol
uring  the  day  before  the  PSG  test,  which  could  increase
naerobic  metabolism  and  thus  uric  acid  production.  The
tudy  protocol  was  approved  by  the  Institutional  Review
oard  Ethics  Committee  of  the  research  hospital.  Informed
onsent  was  obtained  from  each  patient.
olysomnography
olysomnography  was  performed  in  the  Sleep  Laboratory
ith  Embla  polysomnograph  running  Somnologica  software
ersion  4.0  (Flaga  hf.  Medical  Devices,  Iceland)  and  included
our  electroencephalography  (EEG)  channels  (C3  to  A1,  C4
o  A2,  O1  to  A2,  O2  to  A1),  right  and  left  electrooculog-
aphy  (EOG)  channels,  one  chin  electromyography  (EMG)
hannel  and  four  tibialis  anterior  EMG  channels,  ﬁnger  pulse
ximeter,  strain  gauges  for  thoraco-abdominal  movements,
ne  electrocardiography  (ECG)  lead,  a  nasal  airﬂow  (pres-
ure  cannula),  and  a  digital  microphone  to  detect  snoring.
olysomnography  recordings  were  scored  in  30-s  epochs  for
leep,  breathing  and  oxygenation  according  to  the  stan-
UA
Cr
= [(urinary  uric  acid/urina
(urinard  criteria  published  by  the  American  Academy  of  Sleep
edicine  (AASM).18 Obstructive  apneas  were  deﬁned  as  com-
lete  cessation  of  oro-nasal  airﬂow  for  at  least  10  s  in  the
resence  of  chest-wall  motion.  Hypopneas  were  deﬁned  as
c
o
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0%  or  higher  reduction  in  respiratory  airﬂow  with  4%  or
igher  arterial  oxygen  desaturation  or  50%  or  higher  reduc-
ion  in  respiratory  airﬂow  with  3%  or  higher  arterial  oxygen
esaturation  or  an  arousal  with  any  of  the  above  for  at  least
0  s.  AHI  was  calculated  based  on  the  total  number  of  apneas
nd  hypopneas  per  hour  of  sleep.22
alculation  of  UA  excretion  and  overnight  change
n the  UA/creatinine  ratio  (UA/Cr)
wo  urine  samples  were  obtained  from  all  patients  to
alculate  UA  excretion  and  the  UA/Cr  ratio.  The  ﬁrst  uri-
ary  sample  was  obtained  before  PSG  recording  at  night,
nd  the  second  after  the  recording  in  the  morning.  The
pecimens  obtained  at  night  were  kept  at  +4 ◦C.  Urine
amples  were  analyzed  in  the  morning  for  uric  acid  with
ricose  (enzymatic,  calorimetric).  Venous  blood  samples
ere  obtained  and  analyzed  for  creatinine  (calorimetric)
ith  Jafﬂe  method,  BUN  with  urease  (with  kinetic  method),
nd  sodium  with  ion  selective  electrode  (ISE)  on  a  multi-
arameter  analyzer  (Olympus  AU  640;  Olympus  Optical,
okyo,  Japan).  After  5  year  UA  excretion  was  calculated
ccording  to  the  formula  in  mg/dL  unit,  for  the  sample
btained  in  the  morning23:
A  excretion  =
(
urinary  uric  acid
urinary  creatinine
)
×  serum  creatinine
UA/Cr  was  calculated  with  Hasday  and  Grum’s
ethod15:
r)morning −  (urinary  uric  acid/urinary  Cr)night]
uric  acid/urinary  Cr)night
×  100
ulmonary  function  testing
ulmonary  Function  Testing  was  performed  in  the  stand-
ng  position  without  nose  clips  (ZAN  100,  Flowhandy,
ermany).24 Inhaled  salbutamol  400  g  was  administered
nd  the  post-bronchodilator  measurements  were  performed
fter  15  min.  At  least  three,  up  to  ﬁve  forced  expiratory
aneuvers  were  performed  to  obtain  three  technically  sat-
sfactory  blows.  The  highest  FVC  and  FEV1  values  were
eported.
tatistical  analysis
ata  were  expressed  as  frequencies  for  categorical  varia-
les;  and  as  median  (IQR)  or  as  mean  and  standard  deviation
or  continuous  variables,  where  appropriate.  Comparisons
etween  groups  were  tested  by  chi-square  testing  for  cate-
orical  values  and  One-way  Analysis  of  Variance  (ANOVA)  test
or  continuous  variables.  Signiﬁcant  factors  in  the  ANOVA
est  were  analyzed  in  the  pairwise  comparisons  after  Bon-
erroni  correction.  Fisher’s  exact  test  was  used  for  the
omparison  of  categorical  variables,  when  25%  or  more
f  the  expected  cell  counts  were  below  5.  The  univari-
te  correlation  between  UA  metabolites  (UA  excretion  and
UA/Cr)  and  PSG  ﬁndings  were  assessed  with  Spearman
Uric  acid  excretion  in  obstructive  sleep  apnea  and  COPD  21
Table  1  Characteristics  and  polysomnography  ﬁndings  of  the  disease  groups.
Control
(n:  15)
OSAS-NN
(n:  16)
OSAS-NH
(n:  15)
COPD-NN
(n:  15)
COPD-NH
(n:  15)
p
Male  gender,  n  6  13  8  14* 13  0.007
Age (yr)  46.2  (13.0)  51.6  (12.5)  52.8  (7.6)  58.0  (13.3)  58.1  (6.8)  0.02
Smoking status
Current  smoker,  n  3  3  5  6* 4  <0.001
Ex-smoker, n  3  0  1  9  8
Never smoked,  n  8  13  9  0  3
BMI (kg/m2)  27.5  (3.6)  29.6  (2.9)** 33.7  (5.8)  27.2  (3.0)  30.6  (4.8)  <0.001
PSG variables
AHI  0.6  (0.9) 22.4  (15.1)** 62.4  (26.9)*** 1.3  (1.2)  2.6  (1.3)  <0.001
T90% 0.04  (0.13)  0.8  (0.8)  42.7  (26.4)*** 2.8  (2.0)  35.5  (24.3)*** <0.001
Nocturnal SaO2%  mean  96.4  (1.4)  94.8  (1.0)  88.1  (4.2)*** 93.9  (2.2)  87.4  (4.5)*** <0.001
Nocturnal SaO2%  nadir  89.7  (2.8)  85.3  (3.5)  65.3  (9.9)*** 85.2  (3.0)  74.6  (6.5)*** <0.001
UA metabolites
Blood  UA  (mg/dL) 4.8  (1.2)  5.3  (1.5)  5.8  (1.0)  5.5  (1.1)  6.3  (1.7)* 0.059
UA excretion  (mg/dL) 0.37  (0.14) 0.35  (0.08)  0.57  (0.25)* 0.44  (0.14)  0.71  (0.19)*** <0.001
UA/Cr % −11.8  (25.8)  −9.9  (18.3)  42.7  (61.5)** −4.8  (13.3)  22.6  (38.0)  <0.001
Means and (SD)s are given in the table, unless otherwise speciﬁed.
T90%: percentage of total sleep time with SaO2 <90%.
Pairwise comparisons after Bonferroni correction, with control group as the reference.
PSG: polysomnography, BMI: body mass index, UA: uric acid, OSAS NN: obstructive sleep apnea syndrome nocturnal normoxemic, OSAS-
NH: obstructive sleep apnea syndrome nocturnal hypoxemic, COPD-NN: chronic obstructive pulmonary disease nocturnal normoxemic,
COPD-NH: chronic obstructive pulmonary disease nocturnal hypoxemic.
* p < 0.05.
** p < 0.01.
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correlation  coefﬁcients.  Multiple  linear  regression  analysis
was  used  to  assess  the  independent  correlation  between  UA
metabolites  and  PSG  ﬁndings,  after  the  adjustment  for  age,
gender  and  the  factors  related  to  UA  metabolites  in  the
univariate  analysis.  Regression  coefﬁcients  (beta)  and  95%
CIs  were  reported.  Normality  distribution  of  UA  metabolites
was  tested  by  Kolmogorov--Smirnov  test.  For  UA/Cr  val-
ues,  exclusion  of  an  outlier  provided  the  normal  distribution
in  the  linear  regression  analysis.  Change  in  UA  metabolites
after  5  years  was  analyzed  by  Wilcoxon  Signed  Ranks  test.
The  correlation  between  mortality  and  baseline  UA  metabo-
lites  was  tested  by  using  Mann--Whitney  U  test.  A  two-sided
p  value  less  than  0.05  was  considered  to  be  statistically  sig-
niﬁcant  in  all  comparisons.  SPSS  11.0  program  was  used  for
the  statistical  analysis.
Results
Patient  demographics
Patients  were  divided  into  four  treatment  groups  and  one
control  group:  15  patients  with  nocturnal  hypoxemia  (NH)-
COPD,  15  patients  with  nocturnal  normoxemic  (NN)-COPD,
16  patients  with  NN-OSAS,  15  patients  with  NH-OSAS,  and
14  control  subjects.  Of  the  75  study  subjects,  54  were
male  (72%).  There  were  21  current  smokers  and  21  ex-
smokers.  Characteristics  of  the  disease  groups  and  PSG
ﬁndings  are  shown  in  Table  1.  Differences  according  to
a
i
wender,  age,  smoking  status  and  BMI,  AHI,  T90%,  UA  excre-
ion  and  UA/Cr  were  found  to  be  statistically  signiﬁcant
mong  the  patient  groups.
aseline  uric  acid  measurements
A  excretion  signiﬁcantly  correlated  with  age  (correlation
oefﬁcient:  0.37,  p  <  0.01),  BMI  (correlation  coefﬁcient:
.28,  p  < 0.05),  T90%  (correlation  coefﬁcient:  0.57,  p  <  0.01),
octurnal  mean  SaO2 (correlation  coefﬁcient:  −0.54,
 <  0.01)  and  nocturnal  SaO2 nadir  (correlation  coefﬁcient:
0.39,  p  <  0.01).  UA/Cr  correlated  with  AHI  (correlation
oefﬁcient:  0.36,  p  <  0.01),  T90%  (correlation  coefﬁcient:
.52,  p  <  0.01),  nocturnal  mean  SaO2 (correlation  coefﬁ-
ient:  −0.39,  p  <  0.01)  and  nocturnal  SaO2 nadir  (correlation
oefﬁcient:  −0.42,  p  <  0.01).  Table  2  shows  the  correlation
etween  UA  metabolites  and  PSG  variables.
Regression  analysis  revealed  signiﬁcant  correlation
etween  COPD-NH  and  UA  excretion  (beta  coefﬁcient:  0.28,
5%CI:  0.16--0.40).  T90%  was  signiﬁcantly  correlated  with  UA
xcretion  in  the  model  that  included  AHI,  age,  gender  and
MI  (beta  coefﬁcient:  0.005,  95%CI:  0.003--0.007).  AHI  was
ot  signiﬁcantly  associated  with  UA  excretion  in  the  model.
he  correlation  between  UA  excretion  and  disease  groups,
nd  PSG  ﬁndings  adjusted  for  age,  gender  and  BMI  are  shown
n  Table  3.
Regression  analysis  revealed  that  OSAS-NH  and  COPD-NH
ere  signiﬁcantly  correlated  with  UA/Cr  (OSAS-NH,  beta
22  E.  Ozanturk  et  al.
Table  2  Correlation  between  UA  metabolites  and
polysomnography  variables.
UA  excretion  UA/Cr
Age  (yr)  0.37** 0.22
BMI (kg/m2)  0.28* 0.19
AHI 0.15  0.36**
T90%  0.57** 0.52**
Nocturnal  SaO2%  mean  −0.54** −0.39**
Nocturnal  SaO2%  nadir  −0.39** −0.42**
Spearman correlation coefﬁcients are provided in the table.
AHI: apnea-hypopnea index, BMI: body mass index, UA: uric acid.
* p < 0.05.
** p < 0.01.
Table  3  Association  of  uric  acid  excretion  (mg/dL)  with
disease  groups  and  polysomnography  ﬁndings  adjusted  for
age, gender  and  body  mass  index.
Beta  (95%  CI)  R2
Disease  groups
Control  Reference  0.50
OSAS-NN  −0.047  (−0.172  to  0.078)
OSAS-NH  0.115  (−0.019  to  0.248)
COPD-NN  0.032  (−0.100  to  0.165)
COPD-NH  0.270  (0.135  to  0.406)
PSG  variablesa 0.45
AHI −0.002  (−0.003  to  0.000)
T90% 0.005  (0.003  to  0.007)
a Model included age, gender, body mass index, AHI and T90%.
Signiﬁcant ﬁndings are shown in bold type.
PSG: polysomnography, AHI: apnea-hypopnea index, OSAS NN:
obstructive sleep apnea syndrome nocturnal normoxemic, OSAS-
NH: obstructive sleep apnea syndrome nocturnal hypoxemic,
COPD-NN: chronic obstructive pulmonary disease nocturnal nor-
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Table  4  Association  of  UA/Cr  %  with  disease  groups  and
polysomnography  ﬁndings  adjusted  for  age,  gender  and  BMI.
Beta  (95%  CI)  R2
Disease  groups  0.35
Control  Reference
OSAS-NN  6.2  (−16.1  to  28.7)
OSAS-NH  45.9  (21.4  to  70.3)
COPD-NN  8.9  (−15.0  to  32.9)
COPD-NH  37.6  (13.0  to  62.2)
PSG variablesa 0.36
AHI 0.1  (−0.1  to  0.4)
T90% 0.7  (0.4  to  1.1)
a Model included age, gender BMI, AHI and T90%.
Signiﬁcant ﬁndings are shown in bold type.
PSG: polysomnography, AHI: apnea-hypopnea index, OSAS NN:
obstructive sleep apnea syndrome nocturnal normoxemic, OSAS-
NH: obstructive sleep apnea syndrome nocturnal hypoxemic,
COPD-NN: chronic obstructive pulmonary disease nocturnal nor-
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Mortality  signiﬁcantly  correlated  with  baseline  UA  excre-
tion  as  shown  in  Fig.  2. Median  and  IQR  range  were  0.79
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nocturnal hypoxemic.
oefﬁcient:  55.5,  95%CI:  33.7--77.4;  COPD-NH,  beta  coefﬁ-
ient:  43.7,  95%CI:  21.6--65.9).  In  the  model  including  AHI,
ge,  gender  and  BMI,  T90%  displayed  signiﬁcant  correlation
ith  UA/Cr  (beta  coefﬁcient:  0.005,  95%CI:  0.003--0.007).
HI  did  not  signiﬁcantly  correlate  with  UA/Cr  in  the  model.
he  correlation  between  UA/Cr  and  disease  groups,  and
SG  ﬁndings  adjusted  for  age,  gender  and  BMI  are  shown  in
able  4.
ric  acid  measurements  after  the  follow-up
fter  ﬁve  year  follow-up,  58  subjects  could  be  contacted
hile  7  could  not  be  contacted,  and  10  had  deceased  (6  in
OPD-NH,  3  in  COPD-NN  and  1  in  OSAS-NH  group).  Of  these
8  subjects,  35  provided  blood  and  urine  sample  for  UA  mea-
urements  (5  each  in  control,  COPD-NN  and  COPD-NH  groups;
 in  OSAS-NN  and  11  in  OSAS-NH  group).  Of  the  24  patients,
ho  were  offered  NIMV,  11  were  using  NIMV  (0/3  in  COPD-
N,  3/3  in  COPD-NH,  3/9  in  OSAS-NN  and  5/11  in  OSAS-NH).
here  was  no  signiﬁcant  difference  in  terms  of  age,  gen-
er,  BMI,  AHI,  T90%,  UA  excretion  and  UA/Cr  between  the
atients  who  could  be  contacted  and  those  who  could  not  be
F
mmoxemic, COPD-NH: chronic obstructive pulmonary disease
nocturnal hypoxemic.
ontacted.  Eight  patients  in  the  baseline  assessment  and  11
atients  in  the  second  assessment  had  physician-diagnosed
ypertension.  Uric  acid  metabolites  did  not  signiﬁcantly  dif-
er  between  the  patients  with  and  without  hypertension.
Among  the  11  patients,  who  reported  NIMV  usage,  UA
xcretion  after  NIMV  was  signiﬁcantly  lower  than  the  base-
ine  measurement.  There  was  no  signiﬁcant  difference  after
he  5-year  period  in  the  other  patients,  who  did  not  use
IMV  or  were  not  offered  NIMV.  Table  5  shows  the  variation
n  UA  metabolites  between  the  baseline  measurement  and
he  measurement  after  5  years.
ortality  dataVital status
igure  2  Association  between  the  baseline  UA  excretion  and
ortality.
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Table  5  Changes  in  the  uric  acid  metabolites  after  5  years.
Initial  measurement  Second  measurement  p
Not  offered  NIMV  (n:  13)
UA  excretion  (mg/dL)  0.42  (0.34  to  0.68)  0.25  (0.21  to  0.43)  0.06
UA/Cr %  2.5  (−8.3  to  15.8)  −8.8  (−19.5  to  25.6)  0.55
Offered but  not  using  NIMV  (n:  11)a
UA  excretion  (mg/dL)  0.38  (0.25  to  0.55)  0.34  (0.26  to  0.42)  0.37
UA/Cr %  −9.2  (−28.5  to  27.6)  21.5  (−14.2  to  42.5)  0.53
Offered and  using  NIMV  (n:  11)
UA  excretion  (mg/dL)  0.41  (0.36  to  0.57)  0.29  (0.23  to  0.37)  0.01
UA/Cr % −6.1  (−17.3  to  10.6) 8.9  (−0.68  to  37.8) 0.37
Median and (IQR: interquartile range) are given in the table.
NIMV: noninvasive mechanical ventilation.
Signiﬁcant ﬁndings are shown in bold type.
a 2 patients did not provide urine and blood sample for the second m
(0.51--0.89)  and  0.41  (0.31--0.55)  in  the  10  deceased  and  58
surviving  patients,  respectively  (p:  0.001).  However,  mor-
tality  did  not  signiﬁcantly  correlate  with  UA/Cr  which  was
shown  in  Fig.  3.
Among  the  10  deceased  patients,  9  died  from  respira-
tory  causes,  and  for  1  patient  the  cause  of  death  could
not  be  ascertained.  Mortality  was  found  to  be  correlated
with  age,  smoking,  T90%  and  nocturnal  mean  SaO2.  After
the  adjustment  for  age,  mortality  displayed  signiﬁcant  cor-
relation  with  only  nocturnal  SaO2%  mean  (OR:  0.82,  95%CI:
0.69--0.97)  and  UA  excretion  (OR:  231.0,  95%CI:  3.5--1560.3)
(Table  6).
Discussion
This  study,  which  was  conducted  in  a  group  of  patients
including  OSA  and  COPD  patients,  revealed  signiﬁcant  cor-
relation  of  nocturnal  hypoxemia  with  UA  excretion  and
UA/Cr  after  the  adjustment  for  potential  confounders.
Reassessment  of  patients  after  5  years  suggested  that  higher
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Figure  3  Association  between  the  baseline  UA/Cr  and  mor-
tality.
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aseline  UA  excretion  had  higher  mortality.  Among  those
ho  survived  after  ﬁve  years,  there  was  a  decrease  in  UA
xcretion  probably  due  to  PAP  treatment.  Increased  UA
xcretion  in  nocturnal  hypoxemic  OSA  patients  and  signif-
cant  change  in  UA  excretion  after  CPAP  therapy  have  been
eported.15,25 But  to  the  best  of  our  knowledge,  this  is  one
f  the  few  studies  which  found  a  correlation  between  UA
xcretion  and  nocturnal  hypoxemia  in  patient  groups  of  OSA
nd  COPD.
Signiﬁcant  differences  in  UA/Cr  were  found  between
ypoxemic  and  non-hypoxemic  patients  in  previous
tudies.15,26 These  studies,  which  mostly  reported  positive
UA/Cr  values  in  hypoxemic  groups  and  negative  values
n  non-hypoxemic  groups,  are  similar  to  ours.  However,
cKeon  et  al.  did  not  ﬁnd  signiﬁcant  differences  of  UA/Cr
etween  hypoxic  and  non-hypoxic  OSAS  groups  but  there
as  a  signiﬁcant  decrease  in  post-CPAP  UA/Cr  in  the
ypoxic  group.27 As  suggested  by  McKeon  et  al.,  differences
etween  these  studies  might  have  arisen  from  differences
n  standards  for  deﬁning  hypoxemia  and  conditions  under
hich  the  urinary  samples  were  kept.15,26--28 Hasday  and
rum  classiﬁed  the  patients  with  minimum  SaO2 level  below
0%  or  desaturation  score  of  20  as  the  hypoxic  group,  and
ept  urinary  samples  at  −20 ◦C.15 In  two  other  studies,
atients  with  SaO2 <90%  in  minimum  5%  of  total  time  or
ith  SaO2 <90%  for  one  hour  or  with  SaO2 <85%  for  minimum
5  min  were  included  in  the  nocturnal  hypoxemic  group,  and
heir  urinary  samples  were  kept  at  +4 ◦C  with  an  addition
f  5%  sodium  hydroxide.26--28 In  our  study,  patients  who  had
pent  more  than  10%  of  the  sleep  time  with  SaO2 <90%  were
lassiﬁed  as  nocturnal  hypoxemic,  and  the  urinary  samples
ere  kept  at  +4 ◦C  without  5%  sodium  hydroxide  addition.
urthermore,  nocturnal  hypoxemic  patients  in  our  study
ere  likely  to  be  in  a more  severe  condition  than  those  in
he  previous  studies,  which  could  account  for  the  stronger
orrelations  found  between  UA  metabolites  and  nocturnal
ypoxemia  in  our  study.
The  correlation  between  AHI  and  UA  metabolites  did
ot  gain  signiﬁcance  after  the  adjustment  for  nocturnal
ypoxemia.  Accordingly,  the  correlation  between  OSA  and
A  metabolites  might  have  been  mainly  due  to  nocturnal
ypoxemia.  Other  possible  explanations  include  the  weak
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Table  6  Association  between  baseline  characteristics  and  mortality  in  5  years.
Alive
(n:  58)
Death
(n:  10)
p  Adjusted  ORa (95%CI)
Male  gender,  n  18  1  0.13  --
Age (yr)  51  (45  to  60)  62.5  (58  to  69.2)  0.001  --
Smoking status
Ever  smoked,  n  30  9  0.03  9.0  (0.9  to  83.0)
Never smoked,  n  28  1
BMI (kg/m2)  29.8  (27.0  to  32.4)  29.5  (23.2  to  30.5)  0.49  --
PSG variables
AHI  3.9  (0.7  to  30.5)  1.6  (0.4  to  3.1)  0.21  --
T90% 2.4  (0  to  22.7) 25.0  (3.5  to  60.1)  0.01  1.02  (0.99  to  1.05)
Nocturnal SaO2%  mean  94.1  (90.0  to  96.0)  85.7  (79.2  to  88.2)  0.001  0.82  (0.69  to  0.97)
Nocturnal SaO2%  nadir  84.0  (75.7  to  88.2)  82.0  (70.5  to  84.0)  0.11  --
UA metabolites
Blood  UA  (mg/dL)  5.3  (4.7  to  6.2)  6.0  (5.0  to  9.0)  0.09
UA excretion  (mg/dL) 0.41  (0.31  to  0.55)  0.79  (0.51  to  0.89)  0.001  231.0  (3.5  to  15,060.3)
UA/Cr % −1.0  (−14.1  to  10.7) 14.0  (−10.3  to  43.4)  0.16
Median and IQRs are provided in the table unless otherwise speciﬁed.
Signiﬁcant ﬁndings are shown in bold type.
PSG: polysomnography, BMI: body mass index, UA: uric acid, AHI: apnea-hypopnea index.
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ta Adjustments were made for age. For the continuous variables 
orrelation  between  intermittent  hypoxemia  in  OSA  and  UA
etabolites,  and  the  compensation  mechanisms  against  tis-
ue  hypoxia  in  OSA.  Tissue  hypoxia  is  not  merely  determined
ith  arterial  oxygen  saturation.  Other  factors,  including
ardiac  output,  hemoglobin,  hemoglobin  dissociation  curve
nd  peripheral  circulation,  also  inﬂuence  tissue  hypoxia.
issue  hypoxia  in  OSA  could  be  much  more  regulated  by  car-
iovascular  compensation  rate  than  arterial  SaO2.28 These
echanisms  could  be  protective  against  tissue  hypoxemia
n  OSA,  which  might  be  an  explanation  for  the  scarcity  of
egative  UA/Cr  in  OSA  syndrome  patients.
Some  of  the  previous  studies  suggested  that  tanometric
xamination  and  intramucosal  pH  measurement  were  more
alid  indicators  of  tissue  hypoxia  than  PaO2 and  SaO2.27-29
rterial  lactate,  near  infrared  spectrometry,  2--3  diphos-
hoglycerate,  erythropoietin,  monitoring  of  neural  events,
ositron  emission  tomography  and  nuclear  magnetic  reso-
ance  screening  are  also  used  to  indicate  tissue  oxygenation.
ncreased  levels  of  adenosine  were  reported  in  respiratory
iseases  with  hypoxemia,  but  it  is  difﬁcult  and  expensive  to
easure  because  of  its  short  half-life.27,30 Hypoxanthine  and
anthine  are  unstable  intermediate  products.5 Among  ATP
egradation  products,  UA  is  chemically  stable  and  excreted
y  kidneys.  Therefore,  it  is  simple  and  cheap  to  measure.
ur  ﬁndings  could  help  to  enhance  the  use  of  UA  metabo-
ites  as  a  cost-effective  method  for  detecting  tissue  hypoxia
ue  to  nocturnal  hypoxemia  in  patients  with  COPD,  even  in
hose  without  daytime  hypoxia.
The  prognostic  value  of  nocturnal  hypoxemia  has  not
een  proven  for  COPD.31--36 In  our  study,  UA  excretion  was
ssociated  with  nocturnal  hypoxemia.  In  the  reassessment
f  our  patients  after  5  years,  baseline  UA  excretion  as  a
arker  of  tissue  hypoxia  was  found  as  a  predictive  factor
or  mortality  in  the  OSA  syndrome  and  COPD,  even  in  the
h
i
oere calculated for each unit increase.
atients  without  daytime  hypoxemia.  We  found  a  correlation
etween  baseline  UA  excretion  and  mortality  in  5  years.  Mor-
ality  was  mostly  the  case  for  the  COPD  patients,  and  it  was
ssociated  with  respiratory  causes.  CPAP  usage  decreased
A  excretion,  which  suggested  a beneﬁcial  effect  of  CPAP
herapy  on  mortality.  Because  of  the  limitations  of  our  study,
t  is  hard  to  suggest  UA  excretion  as  a  predictive  factor  for
ortality  but  we  consider  it  to  be  promising.  This  hypoth-
sis  could  be  tested  in  a  study  including  a larger  group  of
atients.
The  major  limitations  of  the  present  study  consisted  of  its
mall  sample  size  and  lack  of  objective  data  on  the  factors
hat  could  be  associated  with  mortality  over  the  5  years  and
PAP  use.  Small  sample  size  of  the  study  was  a constraint
or  adjusting  for  the  potential  confounders  in  the  analysis  of
ortality.  The  data  on  characteristics  of  the  patients  were
rovided  from  the  patient  ﬁles.  However,  objective  criteria
ere  used  to  deﬁne  the  cases  of  OSA  syndrome  and  COPD.
ontrol  subjects  consisted  of  patients  who  were  admitted  to
he  sleep  laboratory  with  a  complaint  of  snoring.  Therefore,
hey  may  not  represent  the  general  population.  Despite  the
ata  collected  from  the  patients’  PAP  devices,  we  did  not
ave  objective  evidence  on  the  use  of  NIMV  or  oxygen  ther-
py.  However,  compliance  rate  of  NIMV  was  similar  to  the
revious  studies  in  OSAS.37 We  excluded  patients  with  con-
itions  that  could  affect  the  UA  measurements  but  5  years
onstitute  a  long  period  of  time  for  a  reliable  patient  state-
ent.  Hypertension  was  the  case  for  approximately  15%  of
ur  patients,  which  could  decrease  UA  excretion.  However,
he  analysis  did  not  reveal  a  signiﬁcant  difference  between
ypertensive  and  normotensive  patients.
To  sum  up,  our  ﬁndings  suggest  that  nocturnal  hypoxemia
n  OSA  and  COPD  patients  could  lead  to  comparable  levels
f  tissue  hypoxia,  which  may  be  one  of  the  main  reasons
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for  disease-related  morbidity  and  mortality.  Further  studies
including  more  patients  with  nocturnal  hypoxemia  could
establish  the  relationship  between  UA  excretion  and  mor-
tality.  If  validated,  such  measurements  could  be  used  to
reach  and  monitor  the  high  risk  patients  (‘‘case  ﬁnding’’)
who  could  beneﬁt  more  from  oxygen  and  CPAP  treatment.
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